Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT2A and dopamine D2 receptors, as well as a unique agonist effects on serotonin 5-HT1A receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.
|Number of pages||3|
|Journal||Progress in Neuro-Psychopharmacology and Biological Psychiatry|
|Publication status||Published - 2007 Mar 30|
- Augmentation therapy
- Obsessive-compulsive disorder
ASJC Scopus subject areas
- Biological Psychiatry